Nonpeptidic ligands for peptide and protein receptors

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 395-406

  Freidinger, Roger M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; BRADYKININ RECEPTOR; CHOLECYSTOKININ; ENDOTHELIN; GLUCAGON RECEPTOR; GONADORELIN RECEPTOR; GROWTH HORMONE; LIGAND; MOTILIN; PEPTIDE; RECEPTOR PROTEIN; SOMATOSTATIN RECEPTOR; SUBSTANCE P; VASOPRESSIN;

CHEMISTRY; HUMAN; LIGAND BINDING; MEDICINE; NONHUMAN; RECEPTOR BINDING; REVIEW;

EID: 0033178872     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80060-X     Document Type: Article

References (51)

1. Freidinger RM: Non-peptide ligands for peptide receptors. Trends Pharmacol Sci 1989, 10:270-274.
2. Ripka AS, Rich DH: Peptidomimetic design. Curr Opin Chem Biol 1998, 2:441-452.
3. 4 selectivity. J Am Chem Soc 1998, 120:1368-1373. The first potent, selective nonpeptidic somatostatin receptor subtype 4 agonists, identified through a directed screening approach using peptide pharmacophore information, are described.
4. Yang L, Berk SC, Rohrer SR Mosley RT, Guo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC, Mitra SW et al.: Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci USA 1998, 95:10836-10841. The first potent, selective nonpeptidic somatostatin receptor subtype 2 agonists identified through a directed three-dimensional screening approach using a model for a cyclic hexapeptide bioactive conformation, are described.
5. Pasternak A, Pan Y, Marino D, Sanderson PE, Mosley R, Rohrer SP, Birzin ET, Huskey S-EW, Jacks T, Schleim KD et al.: Potent, orally bioavailable somatostatin agonists: Good absorption achieved by urea backbone cyclization. Bioorg Med Chem Lett 1999, 9:491-496.
6. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen D-M, Xiong Y, Hayes EC, Parmar RM, Foor F et al.: Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282:737-740. Demonstration of the power of combinatorial chemistry combined with high throughput screening to rapidly identify receptor selective leads.
7. Cho N, Harada M, Imaeda T, Imada T, Matsumoto H, Hayase Y, Sasaki S, Furuya S, Suzuki N, Okubo S et al.: Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem 1998, 41:4190-4195.
8. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640-1645. This paper describes the discovery of a new mechanistic approach for treating depression.
9. Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, Ber E, Chicchi GG, Kurtz M, Metzger J et al.: Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 1998, 41:4607-4614.
10. 1 antagonists: Structure-activity relationships and in vivo activity. J Med Chem 1998, 41:4623-4635.
11. 1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J Med Chem 1998, 41:3159-3173.
12. Rosen TJ, Coffman KJ, McLean S, Crawford RT, Bryce DK, Gohda Y, Tsuchiya M, Nagahisa A, Nakane M, Lowe JA III: Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist. Bioorg Med Chem Lett 1998, 8:281-284.
13. Harrison T, Korsgaard MPG, Swain CJ, Cascieri MA, Sadowski S, Seabrook GR: High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template. Bioorg Med Chem Lett 1998, 8:1343-1348.
14. 2 dual antagonists. Bioorg Med Chem Lett 1998, 8:2259-2262.
15. 2) receptor. Bioorg Med Chem Lett 1998, 8:1935-1940.
16. 2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man. J Med Chem 1998, 41:4055-4061. This paper describes the identification of the first potent, orally active bradykinin receptor antagonists.
17. 2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety. J Med Chem 1998, 41:4062-4079.
18. 2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation. J Med Chem 1998, 41:4587-4598.
19. 2 receptor antagonist, FR165649, and agonist, FR190997. Br J Pharmacol 1998, 124:441-446. This is an example of a modest structural change that switches an antagonist to an agonist.
20. 2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. Bioorg Med Chem Lett 1999, 9:463-468.
21. Nargund RP, Patchett AA, Bach MA, Murphy MG, Smith RG: Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential. J Med Chem 1998, 41:3103-3127.
22. Yang L, Morriello G, Patchett AA, Leung K, Jacks T, Cheng K, Schleim KD, Feeney W, Chan WW-S, Chiu S-Hl et al.: 1-[2(R)-(2-Amino-2-methylpropionyl-amino)-3-(1H-indol-3-yl)propionyl]-3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): A potent, orally bioavailable, and short-duration growth hormone secretagogue. J Med Chem 1998, 41:2439-2441.
23. DeVita RJ, Bochis R, Frontier AJ, Kotliar A, Fisher MH, Schoen WR, Wyvratt MJ, Cheng K, Chan Ww-S, Butler B et al.: A potent, orally bioavailable benzazepinone growth hormone secretagogue. J Med Chem 1998, 41:1716-1728.
24. Hansen TK, Ankersen M, Hansen BS, Raun K, Nielsen KK, Lau J, Peschke B, Lundt BF, THøgersen H, Johansen NL et al.: Novel orally active growth hormone secretagogues. J Med Chem 1998, 41:3705-3714.
25. Astles PC, Brealey C, Brown TJ, Facchini V, Handscombe C, Harris NV, McCarthy C, McLay IM, Porter B, Roach AG et al.: Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives. J Med Chem 1998, 41:2732-2744.
26. a antagonist (A-216546). J Med Chem 1998, 41:3261-3275.
27. Murugesan N, Gu Z, Stein PD, Bisaha S, Spergel S, Girotra R, Lee VG, Lloyd J, Misra RN, Schmidt J et al.: Biphenylsulfonamide endothelin antagonists: Structure-activity relationships of a series of mono-and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2′-amino-N-(3,4-dimethyl-5-soxazolyl)-4′-(2-methylpropyl)[1,1′biphenyl]-2-sulfonamide (BMS-187308). J Med Chem 1998, 41:5198-5218.
28. a selective antagonist. Bioorg Med Chem Lett 1998, 8:1771-1776.
29. Sakaki J, Murata T, Yuumoto Y, Nakamura I, Hayakawa K: Stereoselective synthesis of a novel and bifunctional endothelin antagonist IRL 3630. Bioorg Med Chem Lett 1998, 8:2247-2252.
30. Cho N, Nara Y, Harada M, Sugo T, Musuda Y, Abe A, Kusumoto K, Itoh Y, Ohtaki T, Watanabe T et al.: Thieno[2,3-d]pyrimidine-3-acetic acids, a new class of nonpeptide endothelin receptor antagonists. Chem Pharm Bull 1998, 46:1724-1737.
31. Okazaki T, Suga A, Watanabe T, Kikuchi K, Kurihara H, Shibasaki M, Fujimori A, Inagaki O, Yanagisawa I: Studies on nonpeptide angiotensin II receptor antagonists. II. Synthesis and biological evaluation of 5H-Pyrazolo[1,5-b][1,2,4]triazole derivatives with a c-linked oxygen functional group at the 6-position. Chem Pharm Bull 1998, 46:287-293.
32. 2 receptors. J Med Chem 1998, 41:2442-2444.
33. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998, 287:860-867.
34. Bell IM, Erb JM, Freidinger RM, Gallicchio SN, Guare JP Guidotti MT, Halpin RA, Hobbs DW, Homnick CF, Kuo MS et al.: Development of orally active oxytocin antagonists: Studies on 1-(1{4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2-methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. J Med Chem 1998, 41:2146-2163.
35. Zarrinmayeh H, Zimmerman DM, Cantrell BE, Schober DA, Bruns RF, Gackenheimer SL, Ornstein PL, Hipskind PA, Britton TC, Gehlert DR: Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists. Bioorg Med Chem Lett 1999, 9:647-652.
36. 2) receptor antagonist. Bioorg Med Chem Lett 1998, 8:2589-2594. This is another example of the peptoid approach to designing nonpeptidic receptor ligands.
37. Liao S, Alfaro-Lopez J, Shenderovich MD, Hosohata K, Lin J, Li X, Stropova D, Davis P, Jernigan KA, Porreca F et al.: De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the δ-opioid receptor. J Med Chem 1998, 41:4767-4776. The design of a potent nonpeptidic agonist, which mimics the structure and activity of a conformationally constrained cyclic peptide, is described.
38. Wang C, McFadyen IJ, Traynor JR, Mosberg HI: Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models. Bioorg Med Chem Lett 1998, 8:2685-2688.
39. Nagase H, Hayakawa J, Kawamura K, Kawai K, Takesawa Y, Matsuura H, Tajima C, Endo T: Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull 1998, 46:366-369.
40. Thomas JB, Fall MJ, Cooper JB, Rothman RB, Mascarella SW, Xu H, Partilla JS, Dersch CM, McCullough KB, Cantrell BE et al.: Identification of an opioid κ receptor subtype-selective N-Substituent for (+)-(3r,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. J Med Chem 1998, 41:5188-5197.
41. Faghih R, Nellans HN, Plattner JJ: Motilides and motilactides: Design and development of motilin receptor agonists as a new class of gastrointestinal prokinetic drugs. Drugs Fut 1998, 23:861-872.
42. Faghih R, Lartey PA, Nellans HN, Seif L, Burnell-Curty C, Klein LL, Thomas P, Petersen A, Borre A, Pagano T et al.: Synthesis of 9-deoxo-4′-deoxy-6,9-epoxyerythromycin derivatives: Novel and acid-stable motilides. J Med Chem 1998, 41:3402-3408.
43. ReveL L, Makovec F: Update on nonpeptide CCK-B receptor antagonists. Drugs Fut 1998, 23:751-766.
44. Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Pritchard MC, Eden JM, Kneen C, WebdaLe L et al.: Second generation 'peptoid' CCK-B receptor antagonists: Identification and development of N-(adamantyloxycarbonyl)-α-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem 1998, 41:38-45.
45. Padia JK, Field M, Hinton J, Meecham K, Pablo J, Pinnock R, Roth BD, Singh L, Suman-Chauhan N, Trivedi BK et al.: Novel nonpeptide CCK-B antagonists: Design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. J Med Chem 1998, 41:1042-1049.
46. Takeda Y, Kawagoe K, Yokornizo A, Yokomizo Y, Hosokami T, Shimoto Y, Tabuchi Y, Ogihara Y, Otsubo R, Honda Y et al.: Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors II. Chem Pharm Bull 1998, 46:951-961.
47. Darrow JW, Hadac EM, Miller LJ, Sugg EE: Structurally similar small molecule photoaffinity CCK-A agonists and antagonists as novel tools for directly probing 7TM receptor-ligand interactions. Bioorg Med Chem Lett 1998, 8:3127-3132.
48. Wustrow DJ, Capiris T, Rubin R, Knobeisdorf JA, Akunne H, Davis MD, MacKenzie R, Pugsley TA, Zoski KT, Heffner TG et al.: Pyrazolo[1,5-alpyrimidine CRF-1 receptor antagonists. Bioorg Med Chem Lett 1998, 8:2067-2070.
49. Chorvat RJ, Bakthavatchalam R, Beck JP, Gilligan PJ, Wilde RG, Cocuzza AJ, Hobbs FW, Cheeseman RS, Curry M, Resoinito JP et al.: Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines. J Med Chem 1999, 42:833-848.
50. deLaszlo SE, Hacker C, Li B, Kim D, MacCoss M, Mantlo N, Pivnichny JV, ColweLL L, Koch GE, Cascieri MA, Hagmann WK: Potent, orally absorbed glucagon receptor antagonists. Bioorg Med Chem Lett 1999, 9:641-646.
51. Tian S-S, Lamb P, King AG, Miller SG, Kessler L, Luengo JI, Averill L, Johnson RK, Gleason JG, Pelus LM et al.: A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science 1999, 281:257-259. This paper describes the first example of a nonpeptidic small molecule cytokine mimic.